BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Helix Biopharma (CC:HBP) Announces Appointment of Director


12/21/2012 8:27:28 AM

AURORA, ON--(Marketwire - December 20, 2012) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of John A. Rogers to the board of directors. Mr. Rogers's appointment was effective December 18, 2012.

Commenting on the appointment, William White, Chairman of the Board of Helix said, "We are very pleased to have Mr. Rogers serve on our board. He brings a vast knowledge and experience built over 30 years in the life sciences industry and can provide valuable insights to support Helix as it moves forward over the coming years."

Following the appointment of Mr. Rogers, the board is comprised of six directors, five of whom are independent of Helix. The board of directors also appointed William White and Robert Verhagen to the audit committee of the board in place of Messrs. Jack Kay and Thomas Hodgson, who each resigned as directors effective December 14, 2012. Mr. White and Mr. Verhagen will serve on the audit committee until the annual general and special meeting of shareholders scheduled to be held on January 24, 2013. The nominees for election as directors of Helix at this meeting will be included in the management proxy circular to be mailed to shareholders in early January 2013.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".


Investor Relations:
Helix BioPharma Corp.
Tel: 905 841-2300
Email: ir@helixbiopharma.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->